Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of the Effects of PEITC on Oral Cells With Mutant p53
Status: Enrolling
Updated:  11/21/2013
Georgetown Clinical Research Unit
mi
from
Washington,
A Study of the Effects of PEITC on Oral Cells With Mutant p53
Status: Enrolling
Updated: 11/21/2013
Georgetown Clinical Research Unit
mi
from
Washington,
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Scottsdale, AZ
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Las Vegas, NV
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Greenville, SC
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Houston, TX
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Tyler, TX
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  11/25/2013
Clinical Research Facility
mi
from
Vancouver, WA
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 11/25/2013
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
Pinnacle Oncology Hematology; 9055 East Del Camino
mi
from
Scottsdale, AZ
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
Pinnacle Oncology Hematology; 9055 East Del Camino
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
University of Kansas Medical Center; 4350 Shawnee Mission Parkway
mi
from
Fairway, KA
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
University of Kansas Medical Center; 4350 Shawnee Mission Parkway
mi
from
Fairway, KA
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
University of Michigan; 1500 East Medical Center Drive
mi
from
Ann Arbor, MI
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
University of Michigan; 1500 East Medical Center Drive
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
Fox Chase Cancer Center; 333 Cottman Avenue
mi
from
Philadelphia, PA
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
Fox Chase Cancer Center; 333 Cottman Avenue
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
Thomas Jefferson University Hospital; 1025 Walnut Street
mi
from
Philadelphia, PA
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
Thomas Jefferson University Hospital; 1025 Walnut Street
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  11/29/2013
University of Pittsburgh; 300 Halket Street
mi
from
Pittsburgh, PA
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 11/29/2013
University of Pittsburgh; 300 Halket Street
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
City of Hope Medical Group
mi
from
South Pasadena, CA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
City of Hope Medical Group
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Moffitt Cancer Centre and Research Institute
mi
from
Tampa, FL
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Moffitt Cancer Centre and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
UH Case Medical Center
mi
from
Cleveland, OH
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
UH Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated:  12/5/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Enrolling
Updated: 12/5/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
A Feasibility Study of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer Patients
Status: Enrolling
Updated:  12/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
A Feasibility Study of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer Patients
Status: Enrolling
Updated: 12/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients
Status: Enrolling
Updated:  12/10/2013
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients
Status: Enrolling
Updated: 12/10/2013
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated:  12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)
Status: Enrolling
Updated: 12/11/2013
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/11/2013
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/11/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/11/2013
Clinical Research Facility
mi
from
Durham, NC
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/11/2013
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/11/2013
Clinical Research Facility
mi
from
Cleveland, OH
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/11/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Real-Time MV/kV Image Guided Radiation Therapy
Real-Time MV/kV Image Guided Radiation Therapy
Status: Enrolling
Updated:  12/12/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Real-Time MV/kV Image Guided Radiation Therapy
Real-Time MV/kV Image Guided Radiation Therapy
Status: Enrolling
Updated: 12/12/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  12/13/2013
University of California at San Diego
mi
from
San Diego, CA
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 12/13/2013
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated:  12/13/2013
Washington University
mi
from
St. Louis, MO
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Status: Enrolling
Updated: 12/13/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer
Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer
Status: Enrolling
Updated:  12/16/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer
Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer
Status: Enrolling
Updated: 12/16/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated:  12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated: 12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Relative Bioavailability of Pimasertib in Cancer Patients
A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients
Status: Enrolling
Updated:  12/16/2013
Please Contact U.S. Medical Information Located in
mi
from
Rockland, MA
Relative Bioavailability of Pimasertib in Cancer Patients
A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients
Status: Enrolling
Updated: 12/16/2013
Please Contact U.S. Medical Information Located in
mi
from
Rockland, MA
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Aurora, CO
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Washington,
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Miami, FL
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Boston, MA
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated:  12/18/2013
Clinical Research Facility
mi
from
Columbia, SC
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy
Status: Enrolling
Updated: 12/18/2013
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Erlotinib and Temsirolimus for Solid Tumors
Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Status: Enrolling
Updated:  12/19/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Erlotinib and Temsirolimus for Solid Tumors
Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Status: Enrolling
Updated: 12/19/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Precision Research Institute
mi
from
Chula Vista, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Precision Research Institute
mi
from
Chula Vista, CA
Click here to add this to my saved trials
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated:  12/19/2013
Precision Research Institute, LLC
mi
from
San Diego, CA
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy
Status: Enrolling
Updated: 12/19/2013
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials